-
-
-
-
-
-
-
Royalty Pharma Reports Q4 and Full Year 2025 Results
-
-
-
-
-
-
-
Royalty Pharma Acquires Royalty Interest in Alnylam’s AMVUTTRA for $310 Million from Blackstone Life Sciences
-
-
-
-
-
-
-
Royalty Pharma to Acquire Royalty Interest in Amgen’s Imdelltra for up to $950 Million
-
-
-
-
-
-
-
Morgan Stanley Reinstates Royalty Pharma (RPRX) at Overweight
-
-
-
-
-
-
-
Royalty Pharma (RPRX) Announces Sale of MorphoSys Development Funding Bonds
-
-
-
-
-
-
-
Royalty Pharma Reports Third Quarter 2024 Results
-
-
-
-
-
-
-
Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab
-
1,176,867 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

